Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol

INTRODUCTION: Influenza is a major respiratory viral infection of humans with high mortality and morbidity rates and profound economic impact. Although influenza vaccines are generally updated yearly to match the viruses expected in the coming season, genetic mutation and reassortment can result in...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doorn, Eva, Liu, Heng, Ben-Yedidia, Tamar, Hassin, Shimon, Visontai, Ildiko, Norley, Stephen, Frijlink, Henderik W., Hak, Eelko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369918/
https://www.ncbi.nlm.nih.gov/pubmed/28296763
http://dx.doi.org/10.1097/MD.0000000000006339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369918/
https://www.ncbi.nlm.nih.gov/pubmed/28296763
http://dx.doi.org/10.1097/MD.0000000000006339

Ejemplares similares